Literature DB >> 20948459

Ocular side effects associated with peribulbar injections of triamcinolone acetonide for diabetic macular edema.

Emily Y Chew1, Adam R Glassman, Roy W Beck, Neil M Bressler, Gary E Fish, Fredrick L Ferris, James L Kinyoun.   

Abstract

PURPOSE: To evaluate long-term effects of anterior and posterior peribulbar injections of triamcinolone acetonide on intraocular pressure (IOP) elevation and cataract development.
METHODS: This study reports on IOP and cataract progression through 2 years in 96 eyes with diabetic macular edema randomized to focal/grid photocoagulation, 20 mg triamcinolone acetonide anterior injection, anterior injection followed by laser, 40 mg triamcinolone acetonide posterior injection, or posterior injection followed by laser.
RESULTS: Intraocular pressure increased from baseline by ≥ 10 mmHg at ≥ 1 visit through 2 years in 2 eyes (8%) in the laser group, 11 eyes (31%) in the anterior groups, and 6 eyes (17%) in the posterior groups. Among phakic eyes at baseline, 0, 5 (17%), and 1 (3%) in the 3 groups, respectively, underwent cataract surgery before the 2-year visit.
CONCLUSION: Based on this small randomized trial, it appears that over 2 years, anterior peribulbar triamcinolone acetonide injections are associated with an increased incidence of IOP elevation and an increased risk of cataract development compared with laser or posterior peribulbar injections. The association of posterior injections with IOP elevation is less certain. Although the study involved eyes with diabetic macular edema, the results should be relevant to other conditions treated with peribulbar corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20948459      PMCID: PMC3489034          DOI: 10.1097/IAE.0b013e3181f049a8

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  16 in total

1.  Conservative management of refractory steroid-induced glaucoma following anterior subtenon steroid injection.

Authors:  Richard J Hanson; Susan Downes
Journal:  Clin Exp Ophthalmol       Date:  2007-03       Impact factor: 4.207

2.  Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial.

Authors:  Marco A Bonini-Filho; Rodrigo Jorge; José C Barbosa; Daniela Calucci; Jose A Cardillo; Rogério A Costa
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-10       Impact factor: 4.799

3.  Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.

Authors:  José A Cardillo; Luiz A S Melo; Rogério A Costa; Mirian Skaf; Rubens Belfort; Acácio A Souza-Filho; Michel E Farah; Baruch D Kuppermann
Journal:  Ophthalmology       Date:  2005-09       Impact factor: 12.079

4.  Posterior sub-Tenon's capsule triamcinolone injection combined with focal laser photocoagulation for diabetic macular edema.

Authors:  Murat Tunc; Halil Ibrahim Onder; Murat Kaya
Journal:  Ophthalmology       Date:  2005-06       Impact factor: 12.079

5.  The age-related eye disease study (AREDS) system for classifying cataracts from photographs: AREDS report no. 4.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-02       Impact factor: 5.258

6.  Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema.

Authors:  Sophie J Bakri; Peter K Kaiser
Journal:  Am J Ophthalmol       Date:  2005-02       Impact factor: 5.258

7.  A comparison of retrobulbar versus sub-Tenon's corticosteroid therapy for cystoid macular edema refractory to topical medications.

Authors:  A B Thach; P U Dugel; R J Flindall; J O Sipperley; S R Sneed
Journal:  Ophthalmology       Date:  1997-12       Impact factor: 12.079

8.  The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis.

Authors:  C J Helm; G N Holland
Journal:  Am J Ophthalmol       Date:  1995-07       Impact factor: 5.258

9.  Corticosteroid-induced ocular hypertension in the treatment of aphakic or pseudophakic cystoid macular edema.

Authors:  N S Melberg; R J Olk
Journal:  Ophthalmology       Date:  1993-02       Impact factor: 12.079

10.  Drug reflux during posterior subtenon infusion of triamcinolone acetonide in diffuse diabetic macular edema not only brings insufficient reduction but also causes elevation of intraocular pressure.

Authors:  Masahiko Shimura; Kanako Yasuda; Toru Nakazawa; Takashi Shiono; Taiji Sakamoto; Kohji Nishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-04-03       Impact factor: 3.117

View more
  8 in total

Review 1.  Advances in the management of diabetic macular oedema based on evidence from the Diabetic Retinopathy Clinical Research Network.

Authors:  Lik Thai Lim; Seen Nee Chia; Elliott Yann Ah-Kee; Nejia Chew; Manish Gupta
Journal:  Singapore Med J       Date:  2015-05       Impact factor: 1.858

2.  Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide.

Authors:  Chengyun Wang; Huiyuan Hou; Kaihui Nan; Michael J Sailor; William R Freeman; Lingyun Cheng
Journal:  Exp Eye Res       Date:  2014-11-05       Impact factor: 3.467

Review 3.  Drop-free approaches for cataract surgery.

Authors:  Neal H Shorstein; William G Myers
Journal:  Curr Opin Ophthalmol       Date:  2020-01       Impact factor: 4.299

Review 4.  Nanotechnology-based strategies for treatment of ocular disease.

Authors:  Yuhua Weng; Juan Liu; Shubin Jin; Weisheng Guo; Xingjie Liang; Zhongbo Hu
Journal:  Acta Pharm Sin B       Date:  2016-11-18       Impact factor: 11.413

5.  Adverse Drug Reaction Predictions Using Stacking Deep Heterogeneous Information Network Embedding Approach.

Authors:  Baofang Hu; Hong Wang; Lutong Wang; Weihua Yuan
Journal:  Molecules       Date:  2018-12-04       Impact factor: 4.411

6.  Factors associated with visual recovery after sub-Tenon injection of triamcinolone acetonide in diabetic macular edema.

Authors:  Hiroko Kawashima; Kenichi Mizukawa; Junichi Kiryu
Journal:  Clin Ophthalmol       Date:  2012-08-10

7.  Spectral-domain optical coherence tomography in subjects over 60 years of age, and its implications for designing clinical trials.

Authors:  Albert Caramoy; Jonathan Foerster; Elvira Allakhiarova; Carel B Hoyng; Katharina Dröge; Bernd Kirchhof; Sascha Fauser
Journal:  Br J Ophthalmol       Date:  2012-08-03       Impact factor: 4.638

8.  Controlled Release of Dexamethasone From an Intravitreal Delivery System Using Porous Silicon Dioxide.

Authors:  Huiyuan Hou; Chengyun Wang; Kaihui Nan; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-02       Impact factor: 4.799

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.